Chemical Namesolriamfetol
Dosage FormTablet (oral; 75 mg, 150 mg)
Drug ClassInhibitors
CompanyJazz Pharmaceuticals Inc.
Approval Year2019


  • Sunosi is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).
Last updated on 2/5/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Sunosi (solriamfetol) Prescribing Information2019Jazz Pharmaceuticals
Document TitleYearSource
Assessment report – sunosi2019EMA